Literature DB >> 16680600

Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases.

Christian Scheuba1, Klaus Kaserer, Klaus Kaczirek, Reza Asari, Bruno Niederle.   

Abstract

BACKGROUND: Medullary thyroid cancer (MTC) disseminates early to lymph nodes (LN). There is no pre- or intraoperative marker to exclude LN involvement and thereby avoid lateral neck dissection in LN-negative patients.
MATERIALS AND METHODS: This study was intended to verify the observation that patients with MTC lacking desmoplastic stromal reaction (DSR) never have LN metastases. In 120 patients undergoing primary operation for sporadic MTC the prognostic value of DSR with respect to LN involvement was evaluated.
RESULTS: Thirty-two (27%) of 120 tumors were DSR negative, and 88 (73%) were DSR positive. All 32 (100%) DSR-negative tumors were LN negative (N0), and all patients were biochemically cured. Of 88 DSR-positive tumors, 57 (65%) were staged N0, and 31 (36%) were staged N1(LN positive; Fisher's exact test: P = 0.0001). In a comparison of the LN involvement to the DSR characteristics, 32 (36%) of the 89 N0 patients and none of the 31 N1 patients were DSR negative. The sensitivity of DSR in predicting N0 is 38% (95% confidence interval: CI 95% = 27 %-55%), the specificity is 100% (CI 95% = 88%-100%). The sensitivity and specificity for the parameter DSR to differentiate between N0 or N1 were 100% and 36%, respectively.
CONCLUSIONS: The desmoplastic stromal reaction appears to be an excellent intraoperative marker to predict LN involvement with a high specificity but low sensitivity. We therefore propose to avoid initial lateral neck dissection in MTC patients without DSR.

Entities:  

Mesh:

Year:  2006        PMID: 16680600     DOI: 10.1007/s00268-005-0391-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests.

Authors:  C Scheuba; K Kaserer; A Weinhäusl; R Pandev; A Kaider; C Passler; G Prager; H Vierhapper; O A Haas; B Niederle
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

2.  TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.

Authors:  L H Sobin; I D Fleming
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

3.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.

Authors:  E Modigliani; R Cohen; J M Campos; B Conte-Devolx; B Maes; A Boneu; M Schlumberger; J C Bigorgne; P Dumontier; L Leclerc; B Corcuff; I Guilhem
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

4.  Long term prognosis of medullary thyroid carcinoma in 39 patients.

Authors:  P E Voutilainen; M Multanen; R K Haapiainen; C H Haglund; T Sane; A H Sivula
Journal:  Ann Chir Gynaecol       Date:  2000

5.  Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Authors:  K Kaserer; C Scheuba; N Neuhold; A Weinhäusel; O A Haas; H Vierhapper; B Niederle
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

6.  Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection.

Authors:  J F Moley; M K DeBenedetti
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

7.  Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.

Authors:  S Franc; P Niccoli-Sire; R Cohen; S Bardet; B Maes; A Murat; A Krivitzky; E Modigliani
Journal:  Clin Endocrinol (Oxf)       Date:  2001-09       Impact factor: 3.478

8.  Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.

Authors:  Claudia Scollo; Eric Baudin; Jean-Paul Travagli; Bernard Caillou; Nicolas Bellon; Sophie Leboulleux; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

9.  Surgical treatment of medullary thyroid carcinoma.

Authors:  M S Cohen; J F Moley
Journal:  J Intern Med       Date:  2003-06       Impact factor: 8.989

Review 10.  The complexities of breast cancer desmoplasia.

Authors:  R A Walker
Journal:  Breast Cancer Res       Date:  2001-02-01       Impact factor: 6.466

View more
  19 in total

1.  [Intraoperative frozen sections of the thyroid gland].

Authors:  S Synoracki; S Ting; U Siebolts; H Dralle; O Koperek; K W Schmid
Journal:  Pathologe       Date:  2015-07       Impact factor: 1.011

2.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

3.  Is intraoperative calcitonin monitoring useful to modulate the extension of neck dissection in patients with medullary thyroid carcinoma?

Authors:  Carmela De Crea; Marco Raffaelli; Valentina Milano; Cinzia Carrozza; Cecilia Zuppi; Rocco Bellantone; Celestino P Lombardi
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 4.  [Thyroid C cells and their pathology: Part 2: Medullary thyroid carcinoma].

Authors:  S Synoracki; S T Schmid; S Ting; K W Schmid
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

5.  Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia.

Authors:  Oskar Koperek; Astrid Prinz; Christian Scheuba; Bruno Niederle; Klaus Kaserer
Journal:  Virchows Arch       Date:  2009-05-30       Impact factor: 4.064

6.  Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.

Authors:  Sébastien Aubert; Amandine Berdelou; Viviane Gnemmi; Hélène Behal; Robert Caiazzo; Michèle D'herbomez; Pascal Pigny; Jean Louis Wemeau; Bruno Carnaille; Florence Renaud; Brigitte Bouchindhomme; Emmanuelle Leteurtre; Michael Perrais; François Pattou; Christine Do Cao
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

7.  Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis.

Authors:  I Vainas; A Marthopoulos; A Chrisoulidou; K Raptou; K Tziomalos; K Pazaitou-Panayiotou
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

8.  Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis.

Authors:  Jae-Gu Cho; Hyung Kwon Byeon; Kyung Ho Oh; Seung-Kuk Baek; Soon-Young Kwon; Kwang-Yoon Jung; Jeong-Soo Woo
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-17       Impact factor: 2.503

Review 9.  Carcinogenesis and Reactive Oxygen Species Signaling: Interaction of the NADPH Oxidase NOX1-5 and Superoxide Dismutase 1-3 Signal Transduction Pathways.

Authors:  Alessia Parascandolo; Mikko O Laukkanen
Journal:  Antioxid Redox Signal       Date:  2018-11-22       Impact factor: 8.401

10.  The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway.

Authors:  Else Marie Opsahl; Lars Andreas Akslen; Ellen Schlichting; Turid Aas; Katrin Brauckhoff; Anne Irene Hagen; Alf Frimann Rosenlund; Eva Sigstad; Krystyna K Grøholt; Lars H Jørgensen; Trine Bjøro
Journal:  Eur Thyroid J       Date:  2019-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.